Stay updated with breaking news from Randolf Kerschbaumer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Next-generation anti-oxMIF antibody ON203 demonstrates anti-tumor effects through tumor cell death and modulation of the immunosuppressive tumor microenvironment in human tumoroids isolated from
OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, today announced the appointment of three new members to its scientific advisory board
OncoOne Presents Preclinical Proof of Concept Data for its Next-Generation oxMIF-targeted Monoclonal Antibody ON203 at the AACR Annual Meeting
OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the presentation of preclinical proof-of-concept data on its lead candidate